Symposium: Future of Biologic Drug Discovery and Development
Posted on: May 23, 2019
Free to attend, lunch and light dinner will be provided. Join Biocytogen to learn more about the cutting-edge technologies and latest research in biologic drug. The symposium is co-organized by Biocytogen and AcroBiosystem, focusing mainly on therapeutic antibody and biologic drug discovery and development.
Theme: Future of Biologic Drug Discovery and Development
Time: June 13th, 1:00 PM – 6:00 PM
Location: Residence Inn Boston Cambridge, 120 Broadway, Six Cambridge Center, Cambridge, MA
CEO and CSO, Single Cell Technology
CEO, Biocytogen Boston Corp
CSO, LinkedUp Bioscience Inc
1:00 PM – 1:20 PM Registration and Lunch (Lunch box will be provided)
1:20 PM – 1:30 PM Welcome Remarks
1:30 PM – 2:00 PM Introducing AbTheneum, a high throughput and data-rich antibody discovery platform by single Cell Technology
Chun-Nan Chen, CEO and CSO, Single Cell Technology
Named after an institution of great knowledge, AbTheneum™ is Single Cell Technology’s antibody discovery platform. Deploying AbTheneum™, we screen thousands of antibody-secreting cells for binding characteristics and sequence all the cells to return native heavy and light chain sequence pairs correlated with the binding activity for each antibody from single cells.
AbTheneum™ screening assay is flexible and can be customized for any target to find cross-reactivity, epitope specificity, and more. Case studies will be shown for anti-BCMA and anti-FOLR1 antibody leads discovered using AbTheneum™ and their validation data. The discovery of these high-quality and therapeutically relevant antibody candidates highlights the power of AbTheneum™.
2:00 PM – 2:30 PM Accelerating Therapeutic Antibody Candidate Discovery Using Humanized Mouse Models
Qingcong Lin, CEO, Biocytogen Boston Corp
The traditional therapeutic antibody discovery goes from hit generation, to lead screening using in vitro binding and cell-based functional assays to candidate selection using in vivo efficacy study. In this talk, using various humanized mouse models, including IO target humanized mouse models, immune deficient B-NDG based PBMC/CD34+ human immune reconstituted mouse models, CD3e humanized models which are particularly useful for T cell engaged bispecific antibody in vivo efficacy evaluation I like to present an alternative process for throughput and fast for better therapeutic antibody candidate selection. Biocytogen has generated more than 30 IO target single/double humanized mouse models for direct anti-human therapeutic antibody in vivo efficacy, PK/PD studies. Using these proprietary humanized mouse models, you could bypass the dependence on the mouse surrogate or mouse cross-reactive antibodies for preclinical antibody candidate evaluation.
The talk will also present a case study, using target humanized mouse models for high-throughput hit screening to accelerate therapeutic antibody discovery to identify antibody candidates without intensive in vitro binding and cell-based function assays for hit and lead screening, so that to shorten antibody discovery timeline and select better antibody candidates with higher affinity and specificity and better in vivo efficacy.
2:30 PM – 3:00 PM Humanized Mice for Studies of Immunocytokine Mono and Combi-therapies
Stephen Gillies, CSO, LinkedUp Bioscience Inc
Antibody-cytokine fusion proteins (immunocytokines or IC) target the tumor microenvironment where they stimulate a cascade of immune responses based on their interaction with resident tumor, stroma and infiltrating lymphocytes, macrophage and myeloid cells. The goal is to overcome this immune suppressive environment. Due to species specificity of cytokine and cytokine receptor interactions, the best way is to use murine cytokines in syngeneic tumor models or to use humanized NOG mice with the all human antibody and cytokine molecules being developed as potential drugs. Many years ago, in collaboration with Jackson Labs and the University of Tuebingen, we developed models in which CD34+ human hematopoietic stem cells were adoptively transferred into irradiated NOG mice and given weekly doses of long-lasting IL7 (Fc-IL7). This resulted in mice with high numbers of human B, NK and T cells that quickly develop diverse TCR repertoires and have since been shown to be highly functional in IC-induced anti-tumor efficacy. One such IC, NHS-IL12, contains two molecules of species-specific human IL12 and targets DNA that is released into the necrotic regions of all solid tumors, independent of species. Studies include combination therapies with local radiation or with other cytokines leading to some surprising results.
3:00 PM – 3:30 PM Coffee Break and Networking
3:30 PM – 4:00 PM Presentation to be announced
4:00 PM – 4:30 PM Presentation to be announced
4:30 PM – 6:00 PM Dinner Reception (Light dinner will be provided)
Event Date: June 13th, 1:00 PM - 6:00 PM | Event Location: Residence Inn Boston Cambridge, 120 Broadway, Six Cambridge Center, Cambridge, MA